Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) told investors it has received administrative approval for previously announced funding support of about €4 million from the Wallonia Region of Belgium.
Genflow said the non-dilutive support will back continued development of its lead gene therapy candidate GF-1002 for Metabolic Dysfunction-Associated Steatohepatitis, or MASH.
The first instalment is expected no later than May 2026, and the support package spans a three-year development programme, with project-related expenses incurred during 2025 eligible under the terms.
“The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus," said chief executive Dr Eric Leire.
He added: “It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline.”
"As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation."
Genflow also outlined 2026 priorities, including its GF-1004 dog aging study, which began in March 2025 and has an initial efficacy readout expected in the first quarter of 2026, with further results expected in June-July 2026.